Shares in Titan Pharmaceuticals (NSDQ:TTNP) fell yesterday after the pharmaceutical company missed expectations on Wall Street with its second quarter results.
The San Francisco, Calif.-based company posted a net loss of -$3.5 million on sales of $77,000 for the 3 months ended June 30. In the same period last year, Titan posted profits of $11.9 million on sales of $15 million, thanks to a one-time milestone payment following FDA approval of its buprenorphine implant, Probuphine.
Get the full story at our sister site, Drug Delivery Business News.